<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151810</url>
  </required_header>
  <id_info>
    <org_study_id>CDP100003</org_study_id>
    <nct_id>NCT04151810</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dragonboat Biopharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dragonboat Biopharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the safety and tolerability of CDP1 in
      patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine
      the recommended dose (RP2D) for phase II clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary:

      To evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to
      explore the dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for
      phase II clinical trial.

      Secondary:

      To evaluate the pharmacokinetics of CDP1 in patients with advanced solid tumor.

      To evaluate the immunogenicity of CDP1 in patients with advanced solid tumor.

      To evaluate the initial efficacy of CDP1 in patients with advanced solid tumor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>At the end of Cycle 1 (28 days).</time_frame>
    <description>Number of participants with dose limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose (RP2D)</measure>
    <time_frame>At least one cycle of treatment(6 months).</time_frame>
    <description>Recommended phase II dose (RP2D) evaluated on the first cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Observed Maximum Serum Concentration (Cmax) of CDP1 After Infusion</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Pharmacokinetic parameters Cmax for CDP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After Infusion AUC(0-t) for CDP1</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>AUC(0-t) for CDP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-00) After Infusion Pharmacokinetic parameters: AUC(0-00) for CDP1</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Pharmacokinetic parameters: AUC(0-00) for CDP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Apparent Terminal Half-life (t1/2) of CDP1 After Infusion</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Pharmacokinetic parameters T1/2 for CDP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indicators: Number of participants with positive anti-drug antibodies (ADA)</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>Immunogenicity indicators: Number of participants with positive anti-drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indicators: Number of participants with positive neutralizing antibodies</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>Immunogenicity indicators: Number of participants with positive neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>Progression-free survival is defined as the time from the start of treatment with CDP1 until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Tumors</condition>
  <arm_group>
    <arm_group_label>anti-EGFR monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose Phase:This is a dose-escalation trial, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;
Multi-dose Phase:Multiple administrations of three Cohorts of subjects were followed by continuous administration of CDP1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP1</intervention_name>
    <description>Single-dose Phase: Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;
Multi-dose Phase:Cohort 1 Dosing regimen is the first administration of 400mg/m2, followed by 250mg/m2/W;Cohort 2,3 Dosing regimen is the first administration of 500mg/m2, followed by 500mg/m2/2W.</description>
    <arm_group_label>anti-EGFR monoclonal antibody</arm_group_label>
    <other_name>Recombinant anti-EGFR human mouse chimeric monoclonal antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-75 (inclusive), gender unlimited;

          2. Patients with advanced solid tumors confirmed by histology or cytology who have failed
             to receive the existing standard treatment or are unable to tolerate or unwilling to
             accept the standard treatment (tumor types benefiting from anti EGFR treatment,
             including but not limited to colorectal cancer, head and neck squamous cell carcinoma,
             esophageal squamous cell carcinoma, penile squamous cell carcinoma, etc.);

          3. For colorectal cancer patients, RAS / BRAF was detected as wild-type.

          4. ECOG physical strength score: 0-1;

          5. Expected survival time over 3 months;

          6. According to RECIST1.1, there is at least one tumor lesion that can be assessed;

          7. No serious abnormalities of blood system, liver function, renal function and
             coagulation function: Neutrophils ≥1.5×10 9 /L, platelets ≥ 75 × 10 g/L, hemoglobin ≥
             90g/L;Total bilirubin ≤ 1.5ULN, ALT ≤ 2.5ULN, AST ≤ 2.5ULN (ALT ≤ 5ULN, AST ≤ 5ULN in
             patients with liver metastasis); Blood creatinine ≤ 1.5ULN; APTT ≤ 1.5ULN, Pt ≤
             1.5ULN, INR ≤ 1.5ULN;

          8. Eligible fertile patients (male and female) must agree to use a reliable method of
             contraception (hormonal or barrier or abstinence) during the trial and for at least 12
             weeks after the last dose; Women of childbearing age must have a negative blood or
             urine pregnancy test within 7 days of enrollment;

          9. Subjects shall give informed consent to the study before the trial and sign written
             informed consent voluntarily;

        Exclusion Criteria:

          1. Received chemotherapy, biotherapy, radiotherapy, endocrinotherapy, small molecule
             targeted therapy and other anti-tumor treatment (except for nitrosourea, mitomycin C
             and fluorouracil oral drugs) within 4 weeks before starting to use the study drug or
             within 5 half-lives of the known drug (whichever is longer) .6 weeks for nitrosourea
             or mitomycin C; The interval between the last oral administration of fluorouracil,
             such as tegio and capecitabine, and the use of the study drug is at least 2 weeks.

          2. Received other clinical trials within 4 weeks before enrollment, or within 5 half
             lives of known drugs, whichever is the longer elution / withdrawal time;

          3. Have received EGFR inhibitor treatment before;

          4. Patients who had undergone major organ surgery (excluding puncture biopsy) or had
             significant trauma but not recovered within 4 weeks before admission;

          5. The adverse reactions of the previous anti-tumor treatment have not been restored to
             CTCAE 5.0 grade evaluation ≤ 1 (except for hair loss); the radiotoxicity has not been
             restored to CTCAE 5.0 grade evaluation grade 1 and below (except for no effect).

          6. The central nervous system metastasis without treatment or with clinical symptoms is
             not suitable for the group according to the judgment of the researcher; the patients
             suspected of brain or pia mater diseases with clinical symptoms need to be excluded by
             CT / MRI (flow chart notes);

          7. Uncontrolled systemic infection;

          8. Have a history of immunodeficiency, including HIV antibody test;

          9. Treponema pallidum antibody positive;

         10. Patients with chronic hepatitis B virus (HBV) infection, and the number of copies of
             HBV is more than 1000 IU / ml; patients with active hepatitis C virus (HCV) infection
             (note of index flow chart);

         11. Serious cardiovascular disease history: including ventricular arrhythmia requiring
             clinical intervention; acute coronary syndrome, congestive heart failure, stroke or
             other cardiovascular events of level III and above within 6 months; NYHA heart
             function grade ≥ level II or left ventricular ejection fraction (LVEF) &lt; 50%; poor
             control of hypertension, which is judged to be uncomfortable by researchers Join
             group;

         12. Patients with other serious systemic diseases (including respiratory system, endocrine
             system, etc.) who are not suitable for clinical trials according to the judgment of
             researchers;

         13. Known dependence on alcohol or drugs;

         14. People with mental disorder or poor compliance;

         15. Pregnant or lactating women;

         16. In the past, when using biological products drugs, severe transfusion reaction
             occurred;

         17. The investigator believes that the subject is not suitable for this clinical study due
             to any clinical or laboratory examination abnormality or other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang Xiaolei, doctor</last_name>
    <phone>(+86）021-50276381</phone>
    <email>zhangxiaolei@dragonboatbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Qihui, doctor</last_name>
    <phone>(+86）021-5027638</phone>
    <email>Qihui.Wang@dragonboatbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dragonboat Biopharmaceutical,Co.,Ltd</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 3, 2019</last_update_submitted>
  <last_update_submitted_qc>November 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

